Media headlines about OptiNose (NASDAQ:OPTN) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OptiNose earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4108956574215 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- BMO Capital Markets Begins Coverage on OptiNose (OPTN) (americanbankingnews.com)
- OptiNose (OPTN) Coverage Initiated by Analysts at Jefferies Group (americanbankingnews.com)
- Piper Jaffray Begins Coverage on OptiNose (OPTN) (americanbankingnews.com)
- OptiNose (OPTN) Now Covered by Analysts at Royal Bank of Canada (americanbankingnews.com)
- OptiNose Inc (OPTN) Receives Consensus Recommendation of “Strong Buy” from Analysts (americanbankingnews.com)
OPTN has been the subject of a number of analyst reports. Zacks Investment Research lowered OptiNose from a “hold” rating to a “sell” rating in a research note on Saturday, March 17th. Piper Jaffray set a $28.00 price objective on OptiNose and gave the company a “buy” rating in a research note on Monday, January 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $29.25.
OptiNose (NASDAQ:OPTN) last announced its quarterly earnings results on Tuesday, March 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.18). sell-side analysts anticipate that OptiNose will post -3 EPS for the current fiscal year.
In other OptiNose news, CEO Peter K. Miller purchased 5,054 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was bought at an average price of $18.58 per share, with a total value of $93,903.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/04/02/optinose-optn-given-news-sentiment-rating-of-0-11.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.